2nd-qtr 2024 Gilead financials beat expectations

9 August 2024

US biotech Gilead Sciences (Nasdaq: GILD) announced second quarter 2024 financials after markets closed on Thursday, showing thatrevenue increased 5% to $7.0 billion, compared to the same period in 2023, well above analyst expectations of $6.7 billion.

The company also posted earnings per share of $2.01, solidly ahead of estimates of $1.61.

On the basis of the quarter’s strong performance, Gilead raised its full-year profit guidance to $3.60 to $3.90 a share, up from $3.45 to $3.85 a share. It maintained its expectations for 2024 product sales to fall between $27.1 billion and $27.5 billion.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK